Valuation : TAUNS Laboratories,Inc.

Market Cap 5.43TCr 34Cr 29Cr 27Cr 25Cr 47Cr 3.24TCr 47Cr 325.43Cr 126.97Cr 1.64TCr 127.47Cr 124.69Cr P/E 2026 *
10.2x
P/E 2027 * 15.1x
Enterprise Value 6.23TCr 39Cr 34Cr 31Cr 29Cr 54Cr 3.72TCr 54Cr 373.33Cr 145.66Cr 1.88TCr 146.23Cr 143.05Cr EV / Sales 2026
-
EV / Sales 2027 * 3.28x
Free-Float
31.24%
Yield 2026 *
6.93%
Yield 2027 * 5.5%
1 day+1.19%
Current month+7.61%
1 month+7.61%
3 months+2.62%
6 months-7.12%
1 week 499
Extreme 499
512
1 month 463
Extreme 463
512
Current year 463
Extreme 463
568
1 year 463
Extreme 463
582
3 years 401
Extreme 401
733
5 years 401
Extreme 401
733
10 years 401
Extreme 401
733
Manager TitleAgeSince
Chief Executive Officer 51 01/05/2014
Director of Finance/CFO 66 01/11/2018
Corporate Officer/Principal 39 01/07/2022
Director TitleAgeSince
Director/Board Member 51 01/05/2014
Director/Board Member 66 01/09/2020
Director/Board Member 53 01/04/2016
Change 5-day change 1-year change 3-year change Capi.($)
+1.19%0.00%-12.69% - 34Cr
-4.17%-5.38%+150.50%+322.55% 2.17TCr
-0.33%+1.01%-36.12%-21.75% 1.03TCr
-5.10%-5.50%+330.95%+30.27% 801.81Cr
-2.84%-2.44%-32.96% - 724.29Cr
+0.30%+0.80%+81.57%+51.76% 657.75Cr
+2.72%+0.56%-11.59%-13.28% 609.13Cr
-0.49%+1.97%-10.91%-19.13% 440.13Cr
-2.23%-4.02%+71.41%+102.27% 423.17Cr
-1.34%-4.42%-18.97%-26.20% 280.87Cr
Average -1.23%-1.03%+51.12%+53.31% 716.61Cr
Weighted average by Cap. -2.12%-2.10%+83.28%+117.74%

Financials

2026 2027 *
Net sales 1.48TCr 9.22Cr 7.95Cr 7.45Cr 6.8Cr 13Cr 881.58Cr 13Cr 88Cr 34Cr 445.02Cr 35Cr 34Cr 1.93TCr 12Cr 10Cr 9.72Cr 8.88Cr 17Cr 1.15TCr 17Cr 115.36Cr 45Cr 580.6Cr 45Cr 44Cr
Net income 520.13Cr 3.25Cr 2.8Cr 2.63Cr 2.4Cr 4.52Cr 310.75Cr 4.53Cr 31Cr 12Cr 156.86Cr 12Cr 12Cr 359.27Cr 2.25Cr 1.94Cr 1.81Cr 1.66Cr 3.12Cr 214.64Cr 3.13Cr 22Cr 8.4Cr 108.35Cr 8.43Cr 8.25Cr
Net Debt 799.4Cr 5Cr 4.31Cr 4.04Cr 3.69Cr 6.94Cr 477.59Cr 6.96Cr 48Cr 19Cr 241.09Cr 19Cr 18Cr 875.45Cr 5.47Cr 4.72Cr 4.42Cr 4.04Cr 7.6Cr 523.03Cr 7.63Cr 52Cr 20Cr 264.02Cr 21Cr 20Cr
Logo TAUNS Laboratories,Inc.
Tauns Laboratories Inc is a Japan-based company engaged in the business of developing, manufacturing and marketing in vitro diagnostic products and research reagents. The Company operates its business in the in vitro diagnostic products business segment. The Company’s main product is antigen test kit that uses immunochromatography to enable rapid diagnosis at the patient's side without the need for special equipment. The products include ImunoAce Flu, ImunoAce SARSCoV-2 II, ImunoAce SARSCoV-2 Saliva, ImunoAce SARSCoV-2/Flu, ImunoAce Adeno, ImunoAce Strep A Neo, ImunoAce hMPV, ImunoAce Mycopiasma, ImunoAce RSV Neo and ImunoAce Noro.
Employees
218
Date Price Change Volume
28/26/28 JP¥509.00 +1.19% 1,88,000
27/26/27 JP¥503.00 0.00% 1,42,600
26/26/26 JP¥503.00 +0.20% 2,26,700
25/26/25 JP¥502.00 -1.57% 1,36,900
24/26/24 JP¥510.00 +0.20% 2,62,400
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
509.00JPY
Average target price
420.00JPY
Spread / Average Target
-17.49%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 197A Stock